Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protalix BioTherapeutics (PLX) EBT (2016 - 2025)

Historic EBT for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $2.2 million.

  • Protalix BioTherapeutics' EBT fell 4173.82% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year increase of 16762.62%. This contributed to the annual value of $4.2 million for FY2024, which is 5150.6% down from last year.
  • Protalix BioTherapeutics' EBT amounted to $2.2 million in Q3 2025, which was down 4173.82% from $661000.0 recorded in Q2 2025.
  • Protalix BioTherapeutics' 5-year EBT high stood at $19.6 million for Q2 2023, and its period low was -$11.4 million during Q2 2021.
  • Moreover, its 5-year median value for EBT was -$3.2 million (2022), whereas its average is -$1.6 million.
  • In the last 5 years, Protalix BioTherapeutics' EBT crashed by 217987.42% in 2021 and then surged by 46833.52% in 2023.
  • Protalix BioTherapeutics' EBT (Quarter) stood at -$6.6 million in 2021, then soared by 51.47% to -$3.2 million in 2022, then tumbled by 100.19% to -$6.4 million in 2023, then soared by 213.85% to $7.3 million in 2024, then tumbled by 69.4% to $2.2 million in 2025.
  • Its EBT stands at $2.2 million for Q3 2025, versus $661000.0 for Q2 2025 and -$3.7 million for Q1 2025.